Butterfly Network Stock (NYSE:BFLY), Trade Ideas

Butterfly Network

Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional's pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. Butterfly enables the practical application of ultrasound information in the clinical workflow. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. With its small, handheld size, low cost, and simple user interface.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADIL

AGFY

AMRN

ARRY

AUMN

BBWI

BCAN

BEDU

BFLY

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLUE

CMPS

COMM

CRML

CSTL

CTKB

DAVA

DUOL

ENVB

ESTA

FIGS

GRFS

GYRE

HAYW

IHRT

INDP

INSG

IONQ

IRWD

LPSN

MGNI

MIST

MRSN

NARI

NTES

NWTN

OCEA

OKTA

ORIC

PSTG

PZZA

QURE

RNLX

RVNC

SCTL

SDGR

SHLS

SIDU

SNOW

STER

STKL

SWIM

TASK

VERX

VLCN

XMTR

Shares of  Butterfly Network, Inc.  (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Wall Street bull

Equities

Large Cap

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Currency ETFs

Econ #s

Economics

Federal Reserve

Pre-Market Outlook

Tech

ETFs

AVGO

ENPH

MNST

NFLX

NVDA

PLCE

TSLA

PowerShares DB US Dollar Index Bullish Fund

VYGR

Tech stocks drive pre-market surge, Fed inflation data fails to disrupt rate cut expectations. Futures up for Nasdaq, S&amp;P 500, and small caps.

Tech Stocks Set To Rise Thursday As January Inflation Data Fails To Scare Markets, Small Caps Surge

Envoy Medical, Inc. - Class A Common Stock

COCH

ESGL

Shares of  Okta, Inc. (NASDAQ: OKTA) shares rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results and 

Why Okta Shares Are Trading Higher By Around 24%; Here Are 20 Stocks Moving Premarket

Butterfly Network, Inc. Class A Common Stock

Butterfly Network Inc

Butterfly Network Obtains EU MDR Certification For Butterfly iQ+ Devices

Shares of Butterfly Network, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfly#NASDAQ">BFLY</a>) fell sharply during Thursday&rsquo;s session after the company reported mixed fourth-quarter financial results.
Butterfly Network posted GAAP loss of 21 cents per share versus market estimates for a loss of 14 cents per share. The company&rsquo;s quarterly sales came in at sales came in $16.52 million versus estimates of $15.35 million.
Butterfly Network shares dipped 21.7% to $1.1588 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Enveric Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/envb#NASDAQ">ENVB</a>) gained 177.1% to $2.30 after the company announced it has signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of compounds.</li>
<li>Societal CDMO, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sctl#NASDAQ">SCTL</a>) shares climbed 132.7% to $1.07 as the company agreed to be acquired by CoreRx, Inc.</li>
<li>Volcon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vlcn#NASDAQ">VLCN</a>) gained 55.4% to $1.8802 after surging around 39% on Wednesday.</li>
<li>Sidus Space, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sidu#NASDAQ">SIDU</a>) climbed 39.7% to $7.78.</li>
<li>Ocean Biomedical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocea#NASDAQ">OCEA</a>) gained 36.4% to $2.1008. Ocean Biomedical announced joint venture partner, Virion Therapeutics to present clinical study data at 2024 APASL Global Liver Meeting.</li>
<li>Inseego Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/insg#NASDAQ">INSG</a>) rose 34.5% to $3.00.</li>
<li>Vertex, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/verx#NASDAQ">VERX</a>) jumped 29.8% to $32.97 after the company reported better-than-expected fourth-quarter results and issued strong FY24 guidance.</li>
<li>iHeartMedia, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ihrt#NASDAQ">IHRT</a>) rose 29.1% to $2.93 following fourth-quarter results.</li>
<li>Agrify Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agfy#NASDAQ">AGFY</a>) gained 27% to $0.6161. Agrify announced a $3.4 million sales order from New Jersey woman-owned business HarvestWorks Farm.</li>
<li>Renalytix Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnlx#NASDAQ">RNLX</a>) climbed 26.5% to $1.05 after the company announced that effective Mar. 1, the US approved adding the company&#39;s kidneyintelX.dkd to its 10-year Governmentwide Acquisition Contract.</li>
<li>Tutor Perini Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tpc#NYSE">TPC</a>) gained 26% to $11.64 following fourth-quarter results.</li>
<li>Bright Scholar Education Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bedu#NYSE">BEDU</a>) gained 25.3% to $2.3178.</li>
<li>C3.ai, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ai#NYSE">AI</a>) shares rose 24.6% to $37.00 after the company reported better-than-expected third-quarter financial results.</li>
<li>Sterling Check Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ster#NASDAQ">STER</a>) jumped 24.6% to $15.49 after the company agreed to be acquired by First Advantage for approximately $2.2 billion, including outstanding debt.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) gained 24% to $2.00. Adial Pharmaceuticals was awarded a new patent covering AD04 for the potential treatment of opioid use disorder.</li>
<li>Revance Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvnc#NASDAQ">RVNC</a>) jumped 24% to $7.02 after the company reported better-than-expected quarterly financial results.</li>
<li>Latham Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swim#NASDAQ">SWIM</a>) climbed 22.8% to $3.36.</li>
<li>Avidity Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rna#NASDAQ">RNA</a>) jumped 22.5% to $18.70. Avidity Biosciences announced an oversubscribed $400 million private placement.</li>
<li>Pure Storage, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pstg#NYSE">PSTG</a>) rose 21.9% to $51.35 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter revenue guidance above estimates. Also, UBS maintained a Neutral rating on the stock and raised its price target from $38 to $44.</li>
<li>Duolingo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/duol#NASDAQ">DUOL</a>) gained 21.6% to $237.82 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>Okta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/okta#NASDAQ">OKTA</a>) shares rose 19.8% to $104.55 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>Mersana Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrsn#NASDAQ">MRSN</a>) gained 19.5% to $5.80 after the company reported fourth-quarter financial results.</li>
<li>Establishment Labs Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/esta#NASDAQ">ESTA</a>) rose 17.8% to $45.31 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Montrose Environmental Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/meg#NYSE">MEG</a>) gained 16.7% to $38.52 following quarterly results.</li>
<li>ORIC Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/oric#NASDAQ">ORIC</a>) climbed 16.1% to $13.65.</li>
<li>SunOpta Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stkl#NASDAQ">STKL</a>) rose 15% to $6.91 following strong quarterly results.</li>
<li>TaskUs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/task#NASDAQ">TASK</a>) gained 14.4% to $14.17 following upbeat quarterly results.</li>
<li>Magnite, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgni#NASDAQ">MGNI</a>) rose 13.8% to $11.93 following strong quarterly results.</li>
<li>Indaptus Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/indp#NASDAQ">INDP</a>) rose 13.8% to $2.23.</li>
<li>Hayward Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hayw#NASDAQ">HAYW</a>) gained 13.7% to $14.88 following upbeat results.</li>
<li>Hormel Foods Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hrl#NYSE">HRL</a>) rose 12.8% to $34.81 after the company reported better-than-expected first-quarter earnings and reaffirmed FY24 outlook.</li>
<li>Nxu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxu#NASDAQ">NXU</a>) shares rose 9.2% to $0.7750. Nxu said it fully regained compliance with Nasdaq&#39;s continued listing requirements.</li>
<li>NFT Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mi#NYSE">MI</a>) shares jumped 7.9% to $0.2374.</li>
<li>Sprinklr, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cxm#NYSE">CXM</a>) gained 7.9% to $13.56. Sprinklr will replace Veradigm in S&amp;P SmallCap 600 effective prior to opening of trading on March 4, 2024.</li>
<li>Papa John&#39;s International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pzza#NASDAQ">PZZA</a>) climbed 6.8% to $74.89 following strong quarterly earnings.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>J-Long Group Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jl#NYSE">JL</a>) fell 46.3% to $6.86. J-Long Group declared a special cash dividend in aggregate amount of $6 million.</li>
<li>Golden Minerals Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aumn#NYSE">AUMN</a>) dipped 40.4% to $0.3163. Golden Minerals announced that it has elected to stop operations at its Velarde&ntilde;a Properties, located in Durango State, Mexico.</li>
<li>LivePerson, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lpsn#NASDAQ">LPSN</a>) shares declined 40% to $1.43 following fourth-quarter financial results.</li>
<li>NWTN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nwtn#NASDAQ">NWTN</a>) fell 40% to $2.99.</li>
<li>Endava plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dava#NYSE">DAVA</a>) fell 40% to $38.31 following second-quarter earnings.</li>
<li>Kineta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ka#NASDAQ">KA</a>) fell 39.7% to $1.3801 as the company announced intention to explore strategic alternatives.</li>
<li>Ironwood Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irwd#NASDAQ">IRWD</a>) fell 39% to $9.23 after the company&#39;s Phase 3 trial of once-weekly subcutaneous apraglutide did not meet two out of four key secondary endpoints.</li>
<li>Xometry, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xmtr#NASDAQ">XMTR</a>) fell 37.4% to $18.84 after the company reported fiscal fourth-quarter results and issued first-quarter guidance below estimates and disclosed a CFO transition.</li>
<li>Grifols, S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/grfs#NYSE">GRFS</a>) fell 36.7% to $5.91.</li>
<li>The Chemours Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cc#NYSE">CC</a>) shares declined 33.7% to $19.05. Chemours Company named Denise Dignam as the interim CEO and Matt Abbott as the interim CFO. The company also issued preliminary 2023 results.</li>
<li>Bakkt Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bkkt#NASDAQ">BKKT</a>) fell 33.4% to $0.6792 after the company announced two securities purchase agreements.</li>
<li>CommScope Holding Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/comm#NASDAQ">COMM</a>) dipped 30% to $1.2950 after the company reported financial fourth-quarter results below estimates.</li>
<li>Critical Metals Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crml#NASDAQ">CRML</a>) fell 25.2% to $11.43.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) dropped 22% to $19.34.</li>
<li>Lotus Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lot#NASDAQ">LOT</a>) fell 21.8% to $7.71.</li>
<li>BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) shares fell 20.2% to $0.1621. BYND Cannasoft is entering into production agreements for its EZ-G Device.</li>
<li>Snowflake Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snow#NYSE">SNOW</a>) shares tumbled 20.1% to $183.81. Snowflake reported upbeat earnings for its fourth quarter. The company said CEO Frank Slootman has decided to retire from his role as CEO but will continue to serve as chairman of the board. Sridhar Ramaswamy has been appointed as CEO and a member of the board, effective immediately.</li>
<li>Schr&ouml;dinger, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sdgr#NASDAQ">SDGR</a>) shares declined 19.9% to $25.12 after the company reported mixed fourth-quarter financial results.</li>
<li>Castle Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cstl#NASDAQ">CSTL</a>) fell 18.7% to $19.83 following fourth-quarter financial results.</li>
<li>bluebird bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blue#NASDAQ">BLUE</a>) fell 18.2% to $1.3750.</li>
<li>Inari Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nari#NASDAQ">NARI</a>) shares fell 18.1% to $47.50 after posting a loss for the fourth quarter.</li>
<li>WW International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ww#NASDAQ">WW</a>) fell 17.9% to $3.1350 after the company reported fourth-quarter financial results and announced that director Oprah Winfrey has decided not to stand for re-election at the company&#39;s upcoming annual meeting of shareholders.</li>
<li>uniQure N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qure#NASDAQ">QURE</a>) fell 16.7% to $5.57. Goldman Sachs analyst Salveen Richter downgraded uniQure from Buy to Neutral and lowered the price target from $63 to $8.</li>
<li>Amarin Corporation plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amrn#NASDAQ">AMRN</a>) fell 16.7% to $1.09 following quarterly results.</li>
<li>DoubleVerify Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dv#NYSE">DV</a>) declined 16.6% to $32.71 after the company reported fourth quarter financial results.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shls#NASDAQ">SHLS</a>) shares dipped 16.3% to $12.89 after the company reported worse-than-expected fourth-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>Milestone Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mist#NASDAQ">MIST</a>) shares fell 16% to $1.7897 after announcing a proposed public offering of common shares and pre-funded warrants.</li>
<li>COMPASS Pathways plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmps#NASDAQ">CMPS</a>) fell 16% to $10.40 following a wider-than-expected quarterly loss.</li>
<li>FIGS, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/figs#NYSE">FIGS</a>) shares fell 15.4% to $5.10 after the company reported mixed quarterly financial results.</li>
<li>The Lion Electric Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lev#NYSE">LEV</a>) dipped 12.6% to $1.46 following fourth quarter financial results.</li>
<li>Cytek Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctkb#NASDAQ">CTKB</a>) fell 12.2% to $7.67 following fourth quarter financial results.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amc#NYSE">AMC</a>) shares fell 11.1% to $4.4350 following quarterly results.</li>
<li>Titan International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/twi#NYSE">TWI</a>) fell 10% to $12.73 following weak sales.</li>
<li>IonQ, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ionq#NYSE">IONQ</a>) shares declined 7.2% to $10.45 after the company reported mixed fourth quarter financial results.</li>
<li>Array Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arry#NASDAQ">ARRY</a>) fell 5.8% to $13.27.</li>
<li>Bath &amp; Body Works, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bbwi#NASDAQ">BBWI</a>) fell 5.2% to $45.80 after the company reported fourth-quarter earnings and issued worse-than-expected FY24 outlook. It also authorized $500 million stock buyback.</li>
<li>NetEase, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntes#NASDAQ">NTES</a>) shares fell 3.7% to $108.03 after the company reported financial fourth-quarter results below estimates.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/24/02/37390717/nvidia-to-rally-around-27-here-are-10-top-analyst-forecasts-for-thursday"> NVIDIA To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday</a>

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Thursday&#8217;s premarket trading session saw substantial upward momentum propelled by major tech stocks, laying the groundwork for a promising session for <a href="https://www.benzinga.com/markets">U.S. equity indices</a>.
This surge comes as the Fed&#8217;s preferred measure of inflation meets anticipated levels from last month, thereby failing to disrupt expectations of potential interest rate cuts in the <a href="https://www.benzinga.com/news/econ-s/24/02/37392512/feds-preferred-inflation-gauge-matches-expectations-personal-income-soars-thursdays-economic-digest">first half of the year.</a>
Futures on the Nasdaq 100 Index edged up 0.6% to 18,000 points at 8:50 a.m. in New York, poised to fully recover Wednesday&#8217;s losses, according to data from the <a href="https://pro.benzinga.com/dashboard">Benzinga Pro platform</a>. 
Contracts on the S&amp;P 500 rose 0.4% to 5,090 points, reaching levels last observed at the beginning of the week.
The Dow Jones, which has limited exposure to tech stocks, saw only a marginal increase of 0.1%.
The most significant reaction was seen in small-cap stocks, with contracts on the Russell 2000 index, as tracked by the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>), surging by 1.6%.
Yields on Treasury bonds fell, with the 10-year benchmark yield dropping to 4.25%. Market-implied probabilities on a Fed rate cut by June inched higher to 67%, up from Wednesday&#8217;s 62%. 
The U.S. Dollar Index (DXY), as monitored through the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), declined by 0.2% following the inflation data. 
<h3 class="wp-block-heading">Mega-Cap Stock Movers Premarket Thursday</h3>
<h4 class="wp-block-heading">Top Gainers</h4>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Last</td>
<td>Chg</td>
<td>Chg %</td>
</tr>
<tr>
<td>Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)</td>
<td>606.20</td>
<td>9.72</td>
<td>1.63%</td>
</tr>
<tr>
<td>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>1,310.00</td>
<td>20.58</td>
<td>1.60%</td>
</tr>
<tr>
<td>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>787.23</td>
<td>10.60</td>
<td>1.36%</td>
</tr>
<tr>
<td>Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</td>
<td>178.74</td>
<td>2.20</td>
<td>1.25%</td>
</tr>
<tr>
<td>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>204.43</td>
<td>2.39</td>
<td>1.18%</td>
</tr>
</tbody>
</table>
</figure>
<h4 class="wp-block-heading">Worst Performers</h4>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Last</td>
<td>Chg</td>
<td>Chg %</td>
</tr>
<tr>
<td>PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>)</td>
<td>166.00</td>
<td>-1.03</td>
<td>-0.62%</td>
</tr>
<tr>
<td>McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>)</td>
<td>293.52</td>
<td>-1.67</td>
<td>-0.57%</td>
</tr>
<tr>
<td>The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)</td>
<td>206.17</td>
<td>-0.83</td>
<td>-0.40%</td>
</tr>
<tr>
<td>Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>)</td>
<td>196.85</td>
<td>-0.72</td>
<td>-0.36%</td>
</tr>
<tr>
<td>Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>)</td>
<td>54.90</td>
<td>-0.20</td>
<td>-0.36%</td>
</tr>
<tr>
<td>Texas Instruments Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>)</td>
<td>162.50</td>
<td>-0.54</td>
<td>-0.33%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500 Movers Premarket Thursday</h3>
<h4 class="wp-block-heading">Top Gainers</h4>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Last</td>
<td>Chg</td>
<td>Chg %</td>
</tr>
<tr>
<td>Hormel Foods Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRL#NYSE">HRL</a>)</td>
<td>33.13</td>
<td>2.30</td>
<td>7.46%</td>
</tr>
<tr>
<td>Monster Beverage Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>)</td>
<td>58.40</td>
<td>2.55</td>
<td>4.57%</td>
</tr>
<tr>
<td>Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)</td>
<td>83.02</td>
<td>3.34</td>
<td>4.19%</td>
</tr>
<tr>
<td>Enphase Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NYSE">ENPH</a>)</td>
<td>123.89</td>
<td>4.79</td>
<td>4.02%</td>
</tr>
<tr>
<td>Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</td>
<td>137.28</td>
<td>5.22</td>
<td>3.95%</td>
</tr>
</tbody>
</table>
</figure>
<h4 class="wp-block-heading">Worst Performers</h4>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Last</td>
<td>Chg</td>
<td>Chg %</td>
</tr>
<tr>
<td>Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>)</td>
<td>44.80</td>
<td>-3.53</td>
<td>-7.30%</td>
</tr>
<tr>
<td>NiSource Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NI#NYSE">NI</a>)</td>
<td>25.32</td>
<td>-0.53</td>
<td>-2.03%</td>
</tr>
<tr>
<td>HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>)</td>
<td>28.16</td>
<td>-0.56</td>
<td>-1.95%</td>
</tr>
<tr>
<td>CF Industries Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>)</td>
<td>78.64</td>
<td>-1.26</td>
<td>-1.58%</td>
</tr>
<tr>
<td>Dominion Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>)</td>
<td>47.59</td>
<td>-0.76</td>
<td>-1.57%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Russell 2000 Movers Premarket Thursday</h3>
<h4 class="wp-block-heading">Top Gainers</h4>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Last</td>
<td>Chg</td>
<td>Chg %</td>
</tr>
<tr>
<td>The Children&#8217;s Place, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>)</td>
<td>24.98</td>
<td>5.78</td>
<td>30.10%</td>
</tr>
<tr>
<td>Sterling Check Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STER#NASDAQ">STER</a>)</td>
<td>15.61</td>
<td>3.19</td>
<td>25.72%</td>
</tr>
<tr>
<td>Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>)</td>
<td>18.49</td>
<td>3.23</td>
<td>21.17%</td>
</tr>
<tr>
<td>Voyager Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>)</td>
<td>10.85</td>
<td>1.88</td>
<td>20.96%</td>
</tr>
<tr>
<td>Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>)</td>
<td>235.90</td>
<td>40.39</td>
<td>20.66%</td>
</tr>
<tr>
<td>C3.ai, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AI#NASDAQ">AI</a>)</td>
<td>35.28</td>
<td>5.59</td>
<td>18.83%</td>
</tr>
</tbody>
</table>
</figure>
Worst Performers
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Last</td>
<td>Chg</td>
<td>Chg %</td>
</tr>
<tr>
<td>Ironwood Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>)</td>
<td>10.59</td>
<td>-4.53</td>
<td>-29.96%</td>
</tr>
<tr>
<td>Xometry, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>)</td>
<td>21.50</td>
<td>-8.59</td>
<td>-28.55%</td>
</tr>
<tr>
<td>WW International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>)</td>
<td>2.83</td>
<td>-0.98</td>
<td>-25.82%</td>
</tr>
<tr>
<td>Butterfly Network, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>)</td>
<td>1.19</td>
<td>-0.29</td>
<td>-19.59%</td>
</tr>
<tr>
<td>LivePerson, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPSN#NASDAQ">LPSN</a>)</td>
<td>1.93</td>
<td>-0.47</td>
<td>-19.58%</td>
</tr>
<tr>
<td>FIGS, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>)</td>
<td>5.00</td>
<td>-1.03</td>
<td>-17.08%</td>
</tr>
</tbody>
</table>
</figure>
Read now: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37377354/american-express-hits-all-time-high-chart-points-to-upcoming-bull-battle-at-resista">American Express Hits All-Time High: Chart Points To Upcoming Bull Battle At Resistance Line</a>
Wall Street bull illustration created using artificial intelligence via MidJourney.

<h3>Gainers</h3>
<ul>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) stock rose 162.3% to $2.18 during Thursday's pre-market session. The company's market cap stands at $5.9 million. </li>
<li>Societal CDMO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCTL#NASDAQ">SCTL</a>) shares moved upwards by 134.78% to $1.08. The company's market cap stands at $113.1 million. </li>
<li>NeuroBo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRBO#NASDAQ">NRBO</a>) shares increased by 45.11% to $7.43. The company's market cap stands at $36.4 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock moved upwards by 28.97% to $0.89. The market value of their outstanding shares is at $28.7 million. </li>
<li>Establishment Labs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) stock increased by 21.91% to $46.89. The market value of their outstanding shares is at $1.2 billion. As per the press release, Q4 earnings came out yesterday. </li>
<li>Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) shares moved upwards by 20.64% to $18.41. The market value of their outstanding shares is at $1.4 billion. As per the press release, Q4 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) shares decreased by 27.7% to $10.94 during Thursday's pre-market session. The company's market cap stands at $1.7 billion. </li>
<li>Milestone Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) stock fell 20.19% to $1.7. The market value of their outstanding shares is at $56.9 million. </li>
<li>Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) stock fell 14.19% to $1.27. The company's market cap stands at $263.0 million. The company's, Q4 earnings came out yesterday. </li>
<li>Schrodinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) stock fell 13.3% to $27.2. The market value of their outstanding shares is at $1.9 billion. The company's, Q4 earnings came out yesterday. </li>
<li>ClearPoint Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) shares declined by 13.22% to $6.7. The company's market cap stands at $164.9 million. </li>
<li>Ampio Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMPE#AMEX">AMPE</a>) stock fell 13.05% to $2.0. The market value of their outstanding shares is at $2.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMPE

CLPT

NRBO

ONMD

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Shares of Okta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/okta#NASDAQ">OKTA</a>) shares rose sharply in today&rsquo;s pre-market trading after the company reported better-than-expected fourth-quarter financial results and <a href="https://www.benzinga.com/news/earnings/24/02/37378208/okta-stock-rises-on-better-than-expected-q4-results-eps-beat-revenue-beat-upbeat-guidance">issued strong guidance</a>.
Okta reported quarterly earnings of 63 cents per share which beat the analyst consensus estimate of 51 cents. Quarterly sales came in at $605 million which beat the analyst consensus estimate of $587.5 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Okta shares jumped 23.6% to $107.90 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Volcon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vlcn#NASDAQ">VLCN</a>) gained 138% to $2.88 in pre-market trading after surging around 39% on Wednesday.</li>
<li>Societal CDMO, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sctl#NASDAQ">SCTL</a>) shares rose 134.7% to $1.08 in pre-market trading as the company agreed to be acquired by CoreRx, Inc.</li>
<li>J-Long Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jl#NASDAQ">JL</a>) shares surged 38.1% to $17.67 in pre-market trading after dipping over 20% on Wednesday.</li>
<li>Voyager Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vygr#NASDAQ">VYGR</a>) gained 24.4% to $11.16 in pre-market trading after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Nxu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxu#NASDAQ">NXU</a>) shares rose 21.8% to $0.8649 in pre-market trading. Nxu said it fully regained compliance with Nasdaq&#39;s continued listing requirements.</li>
<li>Duolingo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/duol#NASDAQ">DUOL</a>) gained 21.1% to $236.72 in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>C3.ai, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ai#NYSE">AI</a>) shares gained 15.8% to $34.40 in pre-market trading after the company reported better-than-expected third-quarter financial results.</li>
<li>Indaptus Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/indp#NASDAQ">INDP</a>) rose 15.6% to $2.29 in pre-market trading.</li>
<li>NFT Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mi#NYSE">MI</a>) shares jumped 15% to $0.2530 in pre-market trading.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) shares dipped 25.2% to $0.1522 in pre-market trading. BYND Cannasoft is entering into production agreements for its EZ-G Device.</li>
<li>Snowflake Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snow#NYSE">SNOW</a>) shares tumbled 23% to $177.17. Snowflake reported upbeat earnings for its fourth quarter. The company said CEO Frank Slootman has decided to retire from his role as CEO but will continue to serve as chairman of the board. Sridhar Ramaswamy has been appointed as CEO and a member of the board, effective immediately.</li>
<li>WW International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ww#NASDAQ">WW</a>) fell 21.9% to $2.98 in pre-market trading after the company reported fourth-quarter financial results and announced that director Oprah Winfrey has decided not to stand for re-election at the company&#39;s upcoming annual meeting of shareholders.</li>
<li>Envoy Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coch#NASDAQ">COCH</a>) shares declined 19.7% to $2.82 in pre-market trading after jumping 190% on Wednesday.</li>
<li>Butterfly Network, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfly#NASDAQ">BFLY</a>) fell 18.2% to $1.21 in pre-market trading after the company reported mixed fourth-quarter financial results.</li>
<li>ESGL Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/esgl#NASDAQ">ESGL</a>) fell 17.6% to $0.38 pre-market trading after gaining over 5% on Wednesday.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shls#NASDAQ">SHLS</a>) shares dipped 17.6% to $12.68 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>Milestone Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mist#NASDAQ">MIST</a>) shares fell 15% to $1.81 in pre-market trading after announcing a proposed public offering of common shares and pre-funded warrants.</li>
<li>Schr&ouml;dinger, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sdgr#NASDAQ">SDGR</a>) shares fell 15% to $26.66 in pre-market trading after the company reported mixed fourth-quarter financial results.</li>
<li>LivePerson, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lpsn#NASDAQ">LPSN</a>) shares declined 14.6% to $2.05 in pre-market trading following fourth-quarter financial results.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/02/37384835/hp-best-buy-and-3-stocks-to-watch-heading-into-thursday"> HP, Best Buy And 3 Stocks To Watch Heading Into Thursday</a>

WIIM

Butterfly Network shares are trading lower after the company reported mixed Q4 financial results.

U.S. stock futures were lower this morning, with the Dow futures trading lower by over 100 points on Thursday.
Shares of Shoals Technologies Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shls#NASDAQ">SHLS</a>) fell in today&rsquo;s pre-market trading after the company reported worse-than-expected fourth-quarter financial results and issued FY24 revenue guidance below estimates.
Shoals Technologies posted adjusted earnings of 12 cents per share, missing market estimates of 17 cents per share. The company&rsquo;s quarterly sales came in at $130.40 million, missing expectations of $131.94 million.
Shoals Technologies Group shares dipped 17.6% to $12.68 in pre-market trading.
Here are some big stocks recording losses in today&rsquo;s pre-market trading session.
<ul>
<li>Snowflake Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snow#NYSE">SNOW</a>) shares dipped 23% to $177.17. Snowflake reported upbeat earnings for its fourth quarter. The company said CEO Frank Slootman has decided to retire from his role as CEO but will continue to serve as chairman of the board. Sridhar Ramaswamy has been appointed as CEO and a member of the board, effective immediately.</li>
<li>WW International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ww#NASDAQ">WW</a>) dipped 21.9% to $2.98 in pre-market trading after the company reported fourth-quarter financial results and announced that director Oprah Winfrey has decided not to stand for re-election at the company&#39;s upcoming annual meeting of shareholders.</li>
<li>Butterfly Network, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfly#NASDAQ">BFLY</a>) dipped 18.2% to $1.21 in pre-market trading after the company reported mixed fourth-quarter financial results.</li>
<li>FIGS, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/figs#NYSE">FIGS</a>) shares fell 15.3% to $5.11 in pre-market trading after the company reported mixed quarterly financial results.</li>
<li>Schr&ouml;dinger, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sdgr#NASDAQ">SDGR</a>) shares declined 15% to $26.66 in pre-market trading after the company reported mixed fourth-quarter financial results.</li>
<li>The Chemours Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cc#NYSE">CC</a>) shares declined 13% to $24.99 in pre-market trading. Chemours Company named Denise Dignam as the interim CEO and Matt Abbott as the interim CFO. The company also issued preliminary 2023 results.</li>
<li>Inari Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nari#NASDAQ">NARI</a>) shares fell 11.1% to $51.80 in pre-market trading after posting a loss for the fourth quarter.</li>
<li>IonQ, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ionq#NYSE">IONQ</a>) shares declined 8.3% to $10.32 in pre-market trading after the company reported mixed fourth quarter financial results.</li>
<li>Stem, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/stem#NYSE">STEM</a>) shares fell 8.1% to $2.51 in pre-market trading after the company reported worse-than-expected quarterly results.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amc#NYSE">AMC</a>) shares fell 7.8% to $4.60 in pre-market trading following quarterly results.</li>
<li>NetEase, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntes#NASDAQ">NTES</a>) fell&nbsp;5.7% to $105.93 in pre-market trading after the company reported financial fourth-quarter results below estimates.</li>
<li>HP Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hpq#NYSE">HPQ</a>) shares slipped 3.4% to $27.75 in pre-market trading. HP reported in-line earnings for its first quarter, while sales missed estimates. The company said it sees FY24 earnings of $3.25 to $3.65 per share.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/02/37384925/fear-greed-index-remains-in-extreme-greed-zone-pce-data-in-focus"> Fear &amp; Greed Index Remains In &#39;Extreme Greed&#39; Zone; PCE Data In Focus </a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

STEM

Shoals Technologies Posts Weak Q4 Results, Joins Butterfly Network, Schrödinger And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Guidance

Butterfly Network Sees FY24 Low Double-Digit Revenue Growth

<h3>Gainers</h3>
<ul>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) shares moved upwards by 14.6% to $0.4 during Wednesday's after-market session. The market value of their outstanding shares is at $25.4 million. </li>
<li>Establishment Labs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) shares rose 14.43% to $44.01. The market value of their outstanding shares is at $1.1 billion. The company's, Q4 earnings came out today. </li>
<li>Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) shares moved upwards by 11.44% to $10.0. The market value of their outstanding shares is at $555.6 million. As per the press release, Q4 earnings came out today. </li>
<li>Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) shares moved upwards by 9.73% to $84.0. The company's market cap stands at $10.0 billion. As per the press release, Q4 earnings came out today. </li>
<li>MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) shares increased by 9.14% to $8.95. The company's market cap stands at $1.3 billion. As per the press release, Q4 earnings came out today. </li>
<li>Lexaria Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>) shares increased by 9.01% to $2.78. The market value of their outstanding shares is at $33.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) shares decreased by 16.9% to $1.23 during Wednesday's after-market session. The company's market cap stands at $254.7 million. As per the press release, Q4 earnings came out today. </li>
<li>Ampio Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMPE#AMEX">AMPE</a>) shares decreased by 10.87% to $2.05. The company's market cap stands at $2.3 million. </li>
<li>ClearPoint Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) stock fell 10.63% to $6.9. The market value of their outstanding shares is at $169.8 million. </li>
<li>Schrodinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) stock declined by 9.98% to $28.24. The market value of their outstanding shares is at $2.0 billion. The company's, Q4 earnings came out today. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares fell 9.44% to $0.24. The market value of their outstanding shares is at $5.8 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares fell 7.41% to $1.5. The market value of their outstanding shares is at $4.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GCTK

LEXX

MDXG

NTRA

SILO

12 Health Care Stocks Moving In Wednesday's After-Market Session

Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) reported its Q4 earnings results on Wednesday, February 28, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Butterfly Network missed estimated earnings by -62.0%, reporting an EPS of $-0.21 versus an estimate of $-0.13.
Revenue was down $2.47 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.01 which was followed by a 16.0% increase in the share price the next day.
Here's a look at Butterfly Network's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.14</td>
<td>-0.16</td>
<td>-0.21</td>
<td>-0.22</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.13</td>
<td>-0.14</td>
<td>-0.17</td>
<td>-0.17</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>15.28M</td>
<td>18.01M</td>
<td>15.80M</td>
<td>19.93M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>15.42M</td>
<td>18.49M</td>
<td>15.48M</td>
<td>18.98M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Butterfly Network <a href="https://www.benzinga.com/quote/BFLY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Recap: Butterfly Network Q4 Earnings

Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.14) by 50 percent. The company reported quarterly sales of $16.52 million which beat the analyst consensus estimate of $15.35 million by 7.60 percent. This is a 13.00 percent decrease over sales of $18.98 million the same period last year.

Earnings Beats

Earnings Misses

Butterfly Network Q4 2023 GAAP EPS $(0.21) Misses $(0.14) Estimate, Sales $16.52M Beat $15.35M Estimate

Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-02-28. Here's what investors need to know before the announcement.
Analysts estimate that Butterfly Network will report an earnings per share (EPS) of $-0.13. 
Butterfly Network bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.01, which was followed by a 15.6% increase in the share price the next day.
Here's a look at Butterfly Network's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.14</td>
<td>-0.16</td>
<td>-0.21</td>
<td>-0.22</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.13</td>
<td>-0.14</td>
<td>-0.17</td>
<td>-0.17</td>
</tr>
<tr>
<td>Price Change %</td>
<td>16.0%</td>
<td>-9.0%</td>
<td>1.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709053276_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Butterfly Network were trading at $1.33 as of February 26. Over the last 52-week period, shares are down 34.15%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BFLY/earnings">To track all earnings releases for Butterfly Network visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Butterfly Network

Shares of Freshpet, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/frpt#NASDAQ">FRPT</a>) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results.
Freshpet posted quarterly earnings of 31 cents per share, beating market estimates of 5 cents per share. The company&rsquo;s quarterly sales came in at $215.42 million versus expectations of $204.36 million.
Freshpet shares gained 15.5% to $106.29 on Monday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Akili, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akli#NASDAQ">AKLI</a>) shares jumped 126% to $0.5009 after the company reported positive results from Shionogi&#39;s Phase 3 clinical trial of localized version of Akili&#39;s EndeavorRx&reg; for Pediatric ADHD patients in Japan.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zvsa#NASDAQ">ZVSA</a>) climbed 126% to $1.81 after surging over 30% on Friday.</li>
<li>MicroCloud Hologram Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holo#NASDAQ">HOLO</a>) gained 107% to $13.71 after tumbling 40% on Friday.</li>
<li>Neptune Wellness Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nept#NASDAQ">NEPT</a>) rose 54.6% to $0.49.</li>
<li>Interactive Strength Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trnr#NASDAQ">TRNR</a>) surged 32.2% to $0.8701 after the company announced it has entered into an exclusive worldwide distribution agreement with WOODWAY to sell and distribute CLMBR.</li>
<li>Agiliti, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agti#NASDAQ">AGTI</a>) gained 29.4% to $9.89 after the company announced it will be taken private by THL Partners.</li>
<li>Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) surged 28.8% to $143.34 after the company reported better-than-expected financial results.</li>
<li>R1 RCM Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rcm#NYSE">RCM</a>) surged 26.7% to $14.06 after the company received an acquisition offer for the company valued at $13.75 per share.</li>
<li>Butterfly Network, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfly#NASDAQ">BFLY</a>) gained 26.3% to $1.2880.</li>
<li>Altimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alt#NASDAQ">ALT</a>) surged 22.1% to $11.24.</li>
<li>Milestone Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mist#NASDAQ">MIST</a>) gained 21.3% to $2.10 after the company announced plans to resubmit the New Drug Application (NDA) for etripamil to the U.S. Food and Drug Administration (FDA) for paroxysmal supraventricular tachycardia (PSVT).</li>
<li>Ocugen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocgn#NASDAQ">OCGN</a>) climbed 18.9% to $0.9451.</li>
<li>ImmunityBio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ibrx#NASDAQ">IBRX</a>) gained 18% to $ 4.1250.</li>
<li>Li Auto Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/li#NASDAQ">LI</a>) rose 16.2% to $40.44 after the company reported fourth-quarter financial results above estimates and issued first-quarter guidance.</li>
<li>Nuwellis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nuwe#NASDAQ">NUWE</a>) shares rose 16.1% to $0.7101.</li>
<li>SkyWater Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/skyt#NASDAQ">SKYT</a>) gained 15.4% to $10.98.</li>
<li>ImmunityBio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ibrx#NASDAQ">IBRX</a>) gained 14.3% to $3.9999 after dipping 33% on Friday.</li>
<li>Celldex Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cldx#NASDAQ">CLDX</a>) surged 13.9% to $43.00 following strong quarterly sales.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psny#NASDAQ">PSNY</a>) gained 13.4% to $1.4850.</li>
<li>Itron, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/itri#NASDAQ">ITRI</a>) rose 12.3% to $84.11 after the company reported fourth-quarter financial results and issued first-quarter guidance above estimates.</li>
<li>HashiCorp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hcp#NASDAQ">HCP</a>) gained 11.8% to $24.77 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $23 to $30.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mara#NASDAQ">MARA</a>) jumped 11.2% to $26.67.</li>
<li>NeuBase Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nbse#NASDAQ">NBSE</a>) shares surged 10.5% to $0.83. Neubase Therapeutics, on Feb. 22, said board determined for company to dissolve, liquidate and distribute to stockholders its available assets.</li>
<li>Carmell Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctcx#NASDAQ">CTCX</a>) rose 9.9% to $2.47. Carmell announced product development has been completed for Gold Limited Edition Exclusive launch in March 2024.</li>
<li>Domino&#39;s Pizza, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dpz#NYSE">DPZ</a>) gained 8.2% to $469.01 after the company&rsquo;s fourth quarter 2023 earnings surpassed Wall Street expectations, raised its quarterly dividend, and announced an additional share buyback plan.</li>
<li>NIO Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nio#NYSE">NIO</a>) rose 6.5% to $5.75. The company on Monday announced that it entered into a technology license agreement with Forseven Limited.</li>
<li>Teva Pharmaceutical Industries Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/teva#NYSE">TEVA</a>) shares gained 4.3% to $13.44 after the company announced FDA approval of its arthritis treatment.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aclarion, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acon#NASDAQ">ACON</a>) shares fell 62.5% to $0.34 after the company priced its public offering of 5.175 million units. Each unit includes one share of common stock (or a pre-funded warrant), and two common warrants.</li>
<li>Venus Concept Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vero#NASDAQ">VERO</a>) dipped 28.8% to $0.93 after the company announced a $1.2 million registered direct offering at $1.465 per share.</li>
<li>DIH Holding US, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dhai#NASDAQ">DHAI</a>) fell 28.3% to $0.79.</li>
<li>ThermoGenesis Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/thmo#NASDAQ">THMO</a>) dipped 27.5% to $0.7601.</li>
<li>Intuitive Machines, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lunr#NASDAQ">LUNR</a>) fell 25.1% to $7.18 after the company said its lunar lander may have tipped over upon landing on the moon.</li>
<li>Semilux International Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/selx#NASDAQ">SELX</a>) declined 24.4% to $0.8615.</li>
<li>Brera Holdings PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brea#NASDAQ">BREA</a>) fell 21.8% to $0.8601.</li>
<li>Antelope Enterprise Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aehl#NASDAQ">AEHL</a>) dipped 21.8% to $1.50. Antelope Enterprise announced closing of $1.3 million registered direct offering and private placement.</li>
<li>NGM Biopharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ngm#NASDAQ">NGM</a>) fell 19.4% to $1.5399. NGM Bio has entered into a definitive agreement and plan of merger with certain affiliates of the Column Group, LP.</li>
<li>Telesis Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tbio#NASDAQ">TBIO</a>) shares fell 17.8% to $0.6401. Telesis Bio shares jumped 72% on Friday after the company was granted EUR Patent #3503915 for &quot;Genetically Engineered Vibrio Natriegens (Host Organism For Cloning And Manipulating DNA).&quot;</li>
<li>Beneficient (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/benf#NASDAQ">BENF</a>) fell 17% to $0.1640. On Feb. 13, Beneficient posted a third-quarter loss of $1.98 per share.</li>
<li>Dogness (International) Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dogz#NASDAQ">DOGZ</a>) fell 17% to $6.14.</li>
<li>AtlasClear Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/atch#NYSE">ATCH</a>) shares fell 11.2% to $2.3450 after jumping over 131% on Friday.</li>
<li>Jin Medical International Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zjyl#NASDAQ">ZJYL</a>) declined 11.2% to $6.30.</li>
<li>Roma Green Finance Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roma#NASDAQ">ROMA</a>) fell 9.9% to $1.4599 after tumbling 11% on Friday.</li>
<li>Surgery Partners, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgry#NASDAQ">SGRY</a>) dipped 7.8% to $30.43 following weak quarterly sales.</li>
<li>World Acceptance Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wrld#NASDAQ">WRLD</a>) fell 7% to $120.71. World Acceptance recently reported better-than-expected third-quarter financial results.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/24/02/37283655/intuit-to-rally-around-14-here-are-10-top-analyst-forecasts-for-friday"> Intuit To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday </a>

ACON

AEHL

AGTI

AKLI

ATCH

BENF

BREA

CLDX

CTCX

DHAI

DOGZ

FRPT

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

IBRX

ITRI

KRYS

LUNR

MARA

NBSE

NEPT

NUWE

OCGN

PSNY

ROMA

SELX

SGRY

SKYT

TBIO

TEVA

THMO

TRNR

VERO

WRLD

ZJYL

ZVSA

Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) shares rose 121.1% to $0.49 during Monday's regular session. The market value of their outstanding shares is at $38.3 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock rose 69.78% to $1.36. The company's market cap stands at $6.2 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock increased by 66.24% to $2.61. The company's market cap stands at $88.9 million. </li>
<li>Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) stock moved upwards by 39.37% to $155.16. The company's market cap stands at $4.3 billion. The company's, Q4 earnings came out today. </li>
<li>Milestone Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) shares increased by 38.23% to $2.35. The company's market cap stands at $78.6 million. </li>
<li>Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) shares moved upwards by 36.27% to $1.39. The market value of their outstanding shares is at $287.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock decreased by 63.0% to $0.34 during Monday's regular session. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock fell 25.41% to $0.97. The company's market cap stands at $5.3 million. </li>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) shares fell 22.86% to $0.81. The company's market cap stands at $2.5 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares decreased by 20.7% to $2.85. The company's market cap stands at $1.5 million. </li>
<li>NGM Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGM#NASDAQ">NGM</a>) stock declined by 19.51% to $1.54. The market value of their outstanding shares is at $127.1 million. </li>
<li>Concord Medical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) stock fell 18.94% to $0.43. The company's market cap stands at $18.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBLG

12 Health Care Stocks Moving In Monday's Intraday Session

<ul>
<li>Butterfly iQ3 is built on the next-generation P4.3 Ultrasound-on-Chip&#x2122; technology with the world's fastest digital data transfer, enhancing frame rates, frequency and new 3D imaging capabilities – all on a smaller, lighter and more ergonomically designed probe.</li>
<li>Effective today, Butterfly iQ3 is available for purchase via direct sales representatives and Ecommerce in the United States.</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.butterflynetwork.com%2F&amp;esheet=53895636&amp;newsitemid=20240213652085&amp;lan=en-US&amp;anchor=Butterfly+Network%2C+Inc.&amp;index=1&amp;md5=53d78b636596ae01df61d76c47aecc38">Butterfly Network, Inc.</a>&nbsp;("Butterfly", "the Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, announced today the commercial launch of its third-generation handheld point-of-care ultrasound (POCUS) system, Butterfly iQ3&#x2122;, which&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.butterflynetwork.com%2Fpress-releases%2Ffda-clearance-butterfly-iq3&amp;esheet=53895636&amp;newsitemid=20240213652085&amp;lan=en-US&amp;anchor=received&amp;index=2&amp;md5=74d696ceb26b4dd8ee49c37cd30ce780">received</a>&nbsp;FDA clearance last month. Butterfly iQ3 is powered by the Company's most advanced semiconductor chip with a data transfer rate that is double that of its predecessor. The result is unparalleled image quality and faster micro-beamforming for advanced 3D capabilities: iQ Slice&#x2122; and iQ Fan&#x2122;.
This press release features multimedia. View the full release here:&nbsp;<a href="https://www.businesswire.com/news/home/20240213652085/en/">https://www.businesswire.com/news/home/20240213652085/en/</a>
&nbsp;
"Butterfly iQ3 is a pivotal moment in Butterfly's trajectory, further validating the company's initial hypothesis that semiconductor-based digital ultrasound is not only viable, but the future of all ultrasound," said Joseph DeVivo, Butterfly Network's President, Chief Executive Officer, and Board Chairman. "With the introduction of iQ3, we're witnessing a paradigm shift in ultrasound. iQ3 sets a new standard where digital image quality matches that of traditional handheld devices, and even certain carts. This device will attract more seasoned POCUS experts to choose Butterfly and support new learners to gain confidence and competency through artificial intelligence and advanced imaging tools."
Unparalleled image quality.
Butterfly iQ3 brings best-in-class, high-resolution image quality with twice the processing power compared to Butterfly iQ+ and a novel "no focus" rubber lens, enabling providers to intuitively identify anatomy, observe small structures, and ultimately, make more confident diagnostic decisions. In a blind survey distributed by third-party vendor, Intellisurvey, 475 clinicians across more than eight specialties compared Butterfly iQ3 images to GE Vscan Air&#x2122; CL, with the majority across all categories ranking iQ3's overall image quality better than that of GE Vscan Air&#x2122; CL.&#x2A;
"Healthcare is at a cornerstone in the adoption of point-of-care ultrasound. Bedside ultrasound has the potential to vastly increase the information available to clinicians for proper assessment, intervention, and prevention of cardiovascular diseases and other conditions across the human body," said Partho Sengupta, MD, Henry Rutgers Professor and Chief of Cardiology at Rutgers Robert Wood Johnson Medical School and Robert Wood Johnson University Hospital. "I use Butterfly in my clinical practice and in clinical research. The introduction of Butterfly iQ3 includes a focus on higher precision capabilities for cardiovascular point-of-care ultrasound applications to inform complex decisions. In my early experience, I found that the enhancements in visualization technology and artificial intelligence, as well as image quality will greatly assist health care professionals in our efforts to continually improve outcomes for our patients."
Novel tools: iQ Slice and iQ Fan.
Launching on Butterfly iQ3 are two new, advanced 3D imaging capabilities designed to make image capturing easier: iQ Slice and iQ Fan. These tools join Butterfly's existing robust feature list of over 20 anatomical presets, six imaging modes (B-Mode, M-Mode, Color Doppler, Power Doppler, Pulsed-Wave Doppler, and Biplane Imaging&#x2122;) and collection of artificial intelligence (AI) and advanced imaging tools (e.g, Auto Bladder Volume Capture, Auto B-Line Counter, NeedleViz&#x2122;, and a rich set of Calculation tools).
<ul>
<li>Butterfly iQ Slice: The world's first automated, sequential ultrasound capture mode on a handheld device, made uniquely possible by Butterfly's proprietary Ultrasound-on-Chip&#x2122; technology. iQ Slice automatically steers the beam to scan an organ and capture up to 46 ultrasound slices at a time across a wide angle. The imaging mode is designed to make it easier and faster to acquire excellent images without skilled maneuvering. These files can either be immediately read and measured at the bedside by skilled scanners, or for those less experienced, can be sent to a specialist for further review – similar to the workflow of a CT or MRI.</li>
<li>Butterfly iQ Fan:&nbsp;A dedicated lung tool that further builds on the core iQ Slice technology to allow providers to benefit from real-time, back-and-forth virtual fanning, making it easier to visualize A-lines and other lung conditions. With iQ Fan the user no longer needs to manually fan the probe, and can just focus on analyzing the images.</li>
</ul>
"The next-generation P4.3 chip we developed with TSMC (["Taiwan Semiconductor Manufacturing Company Limited", NYSE:<a href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), the world's leading semiconductor foundry, is the foundation for the Butterfly iQ3 hardware platform. From the micron-sized MEMS1&nbsp;that transmit and receive ultrasound to the electronics and mechanical heat dissipation, we've improved device performance across the board. Our customers will have a seamless experience that's fully integrated across hardware, mobile app, and enterprise software." said Andrei Stoica, PhD, Chief Technology Officer, Butterfly Network.
"TSMC has partnered with Butterfly to push the boundaries of ultrasound imaging through innovative CMOS-MEMS2&nbsp;integration and our latest collaboration in delivery of Butterfly iQ3 represents our joint research and development efforts, resulting in incredibly advanced imaging capabilities," said Lucas Tsai, Senior Director of Market Development and Emerging Business Management, TSMC North America. "TSMC continues to put substantial effort into developing more advanced CMOS and MEMS technologies to enable our customers like Butterfly to unleash semiconductor innovation for applications from traditional motion sensing to microphone, bio-sensing, micro-speakers, and medical ultrasound to enhance human convenience, health, and safety."
The new shape of ultrasound: enhanced comfort and efficiency.
Butterfly iQ3 features a new user-centric ergonomic design that is smaller, lighter and better distributed, and with even stronger battery:
<ul>
<li>17%&nbsp;smaller probe face&nbsp;allows for better intercostal access for cardiac and lung imaging, as well as vascular access.</li>
<li>7%&nbsp;shorter probe with ergonomic weight distribution&nbsp;designed to reduce the physical strain on scanners and ensure better control and maneuverability, which allows for more precise and comfortable scans.</li>
<li>3 configurable control buttons&nbsp;can be tailored for functionality, allowing for user-friendly, seamless navigation, quick scans and interpretations, saving critical time during diagnoses.</li>
<li>2.5x faster charge time&nbsp;than Butterfly iQ+ and up to&nbsp;2 hours of thermal run time&nbsp;for outstanding continuous scanning.</li>
</ul>
Butterfly Network's Chief Medical Officer, John Martin, MD, concludes, "With Butterfly iQ3, we set out to give clinicians the clear leading solution in point-of-care ultrasound. We built this device to meet the needs of the end user every step of the way, whether they're an advanced scanner or just starting out, and we achieved this. We delivered a probe that will always be ready for them. Immediate boot up to clear imaging, long run time, fit-in-hand comfort, customizable controls, and rapid charging… all at a price that's still below incumbents."
As of today, February 13, 2024, Butterfly iQ3 is now commercially available to healthcare providers in the United States for&nbsp;$3,899&nbsp;plus membership. To learn more about the Butterfly iQ3 or to purchase, visit:&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.butterflynetwork.com%2Fiq3&amp;esheet=53895636&amp;newsitemid=20240213652085&amp;lan=en-US&amp;anchor=www.butterflynetwork.com%2Fiq3&amp;index=3&amp;md5=6bbecda0ebe0c8aeb6cf0041030e2259">www.butterflynetwork.com/iq3</a>
Butterfly will host a Virtual Launch Event today, February 13, 2024, from 4:30-6:00 pm ET featuring product demonstrations and thought leader discussion:&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbutterflynetwork.zoom.us%2Fwebinar%2Fregister%2FWN_-2UDOqfbQn6CdMSkoSFwyw%23%2Fregistration&amp;esheet=53895636&amp;newsitemid=20240213652085&amp;lan=en-US&amp;anchor=view+details+and+register.&amp;index=4&amp;md5=0dc596b6b318966d2afa217c3455796f">view details and register.</a>
The news follows Butterfly's release of&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.butterflynetwork.com%2Feducation%23scanlab&amp;esheet=53895636&amp;newsitemid=20240213652085&amp;lan=en-US&amp;anchor=ScanLab%26%238482%3B&amp;index=5&amp;md5=eb12436193dd5d9b494f3851c1d73d89">ScanLab&#x2122;</a>&nbsp;last month, a separate AI-powered educational application for ultrasound scanning practice that is available for download to all Butterfly members at no additional cost, and is compatible with Butterfly iQ3, as well as prior generations.

Global

Butterfly Network Launches Next-Generation Butterfly iQ3 In The United States, Which Received FDA Clearance Last Month

<ul>
<li>Butterfly iQ3 is built on the next-generation P4.3 Ultrasound-on-Chip&trade; technology with the world&#39;s fastest digital data transfer, enhancing frame rates, frequency and new 3D imaging capabilities - all on a smaller, lighter and more ergonomically designed probe.</li>
<li>Effective today, February 13, 2024, Butterfly iQ3 is available for purchase via direct sales representatives and Ecommerce in the United States.</li>
</ul>

Butterfly Network Launches Next-Generation Butterfly iQ3 In The United States

<h3>Gainers</h3>
<ul>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) stock increased by 39.2% to $0.71 during Monday's after-market session. The company's market cap stands at $54.7 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock rose 14.52% to $0.38. The company's market cap stands at $2.3 million. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock increased by 10.22% to $1.94. The market value of their outstanding shares is at $34.5 million. </li>
<li>Oncternal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCT#NASDAQ">ONCT</a>) shares increased by 9.56% to $10.93. The company's market cap stands at $32.3 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock rose 8.21% to $1.05. The company's market cap stands at $2.1 million. </li>
<li>Alaunos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) stock moved upwards by 7.79% to $0.17. The company's market cap stands at $40.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares decreased by 12.6% to $1.18 during Monday's after-market session. The company's market cap stands at $38.0 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares declined by 10.95% to $0.85. The market value of their outstanding shares is at $7.9 million. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock fell 6.77% to $0.74. The market value of their outstanding shares is at $168.1 million. </li>
<li>Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) shares declined by 6.53% to $1.0. The market value of their outstanding shares is at $207.1 million. </li>
<li>Soleno Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) stock declined by 6.11% to $45.06. The company's market cap stands at $1.3 billion. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock decreased by 5.51% to $0.17. The market value of their outstanding shares is at $1.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADAP

ATPC

CNSP

EKSO

NAOV

ONCT

PALI

SLNO

TCRT

12 Health Care Stocks Moving In Monday's After-Market Session

Butterfly Network Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) shares are trading higher after the company said it sees higher-than-expected&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/01/b36602723/butterfly-network-provides-business-update-during-42nd-annual-j-p-morgan-healthcare-conference-pre" rel="noreferrer noopener">FY23 revenue and profits.</a>
The company expects to exceed FY23 revenue and adjusted EBITDA loss guidance of at least $64 million (vs. consensus: $64.54 million) and&nbsp;<a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">$(75) million &#8211; $(70) million.</a>
The company plans to launch a handheld ultrasound system, Butterfly iQ3, in Q1 2024, as it got&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/01/b36531979/butterfly-network-announces-fda-clearance-of-its-next-generation-handheld-ultrasound-system-butter" rel="noreferrer noopener">FDA clearance this week</a>.
The new device is BFLY&#8217;s third iteration of the world&#8217;s first semiconductor-based single-probe, whole-body ultrasound system.&nbsp;
&#8220;Four days ago, we announced that we received FDA clearance for our third-generation device, Butterfly iQ3,&#8221; Butterfly president and CEO Joseph DeVivo said. &#8220;The power in this device is equivalent to 20,000 4K movies running simultaneously. It allows us to not only get tremendous imaging, but also do calculations and develop new tools, like iQ Slice, that transform how ultrasound is captured.&#8221;
Price Action: BFLY shares are up 7.34% at $1.1700 premarket on the last check Friday.
Now Read: <a href="https://www.benzinga.com/news/24/01/36541251/why-rxsight-shares-are-trading-higher-by-20-here-are-other-stocks-moving-in-mondays-mid-day-session">Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday&#8217;s Mid-Day Session</a>

Digital Health Company Butterfly Network Shares Up: What's Going On?

The company&#39;s previously issued&nbsp;guidance&nbsp;for the full year 2023 was revenue of at least&nbsp;$64 million, and an improved adjusted EBITDA loss of&nbsp;$75&nbsp;- 70 million.

Butterfly Network Reveals Expectation To Exceed 2023 Revenue And Adjusted EBITDA Guidance; Expects To Launch Butterfly iQ3 This Quarter, Q1 2024

Ampio Pharmaceuticals, Ironwood, Incannex among healthcare movers

Thursday, February 29, 2024 - Butterfly Network Inc (BFLY) reported downside earnings and upside revenues.Butterfly Network Inc's earnings came in at an EPS loss of $0.21 per share, 62% lower than estimates for an EPS loss of $0.13 per share. The firm's loss per share expanded by 24% since reporting a loss of $0.17 per sha

Butterfly Network Inc Down 21.62% To $1.18 After Earnings Miss

Butterfly Network, Inc. (BFLY) has disclosed a new risk, in the Innovation / R&D category. Butterfly Network, Inc., while pioneering technology on ...

Bad News for Butterfly Network, Inc. Stock: This New Risk Has Been Added